Oncopeptides

Description

Oncopeptides develops peptide drug conjugates that use tumor-overexpressed peptidases and esterases to release an alkylating payload intracellularly, aiming to damage DNA and treat difficult-to-treat cancers such as multiple myeloma and glioblastoma.

Oncopeptides is located in the Stockholm ecosystem.

Related

• EnzyTagEnzyTag develops peptiligase-based synthetic routes for manufacturing peptide new chemical entities, small proteins, and peptide…
• AnaCardioAnaCardio develops novel inotropic drugs that act via the ghrelin signalling pathway to increase cardiomyocyte contractility and cardiac…
• Devyser DiagnosticsDevyser Diagnostics develops DNA test kits and integrated software for laboratory DNA diagnostics, helping labs run genetic testing…
• ElektaElekta develops radiotherapy, brachytherapy and imaging systems for precision radiation medicine used by hospitals and cancer centres to…
• OrexoOrexo develops powder-based drug delivery technologies and therapeutic formulations, including AmorphOX®, used to improve bioavailability…
• SNIPR BIOMESNIPR BIOME develops CRISPR-based medicines that use bacteriophages, engineered probiotics, and CRISPR systems to target…
• CimCureCimCure develops cancer vaccines using its proprietary iBoost conjugate technology to induce immune responses that target and destroy…
• Rab DiagnosticsRab Diagnostics develops biomarker tools, assays and the RabCANCER platform to predict antibody–drug conjugate response for pharma…
• 3H Biomedical3H Biomedical supplies primary human and animal cell-based products, RNA, DNA, assays and culture media for life science research, drug…